X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Press Statements

Dr Reddy’s Lab gets emergency use authorisation for Sputnik V in India

Content Team by Content Team
20th April 2021
in Press Statements
Dr Reddy's Lab gets emergency use authorisation for Sputnik V in India

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Dr. Reddy’s Laboratories Ltd. announced that it has received the permission from the Drug Controller General of India(DCGI)to import the Sputnik vaccine into India for restricted use in emergency situationsas per the provisions of the New Drug and Clincial Trials rules, 2019 under the Drugs and Cosmetics Act

In September 2020, Dr. Reddy’s had partnered with the Russian Direct Investment Fund (RDIF) to conduct the clinical trials of Sputnik Vand distribute the vaccine in India.In addition to the trials conducted in Russia by RDIF. Phase II / III clinical trials of the vaccine were carried out by Dr. Reddy’s in India.

Dr Reddy’s Laboratories co-chairman and managing director GV Prasad said, “We are very pleased to obtain the emergency use authorizationfor Sputnik Vin India. With the rising cases in India, vaccination is the most effectivetool in our battleagainst COVID-19. Thiswill enable us to contribute to our nation’s effort of vaccinatinga signficant proportion of our population.”

Sputnik V is now approved for use in 60countries around the world. Itranks second among coronavirus vaccines globally in terms of the number of approvals issued by government regulators. Sputnik V uses two different vectors for the two shots in a course of vaccination.The efficacy of Sputnik V was determined to be 91.6% as per a published article in the Lancet, one of the world’s oldest and most respected medical journals.

About Dr. Reddy’s:
Dr. Reddy’s Laboratories Ltd. is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses -Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products –Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include –USA, India, Russia & CIS countries, and Europe.

Previous Post

Fujifilm Diosynth Biotechnologies Biologics Production Facility Expansion

Next Post

FDA accepts Airway Therapeutics IND application for Covid-19

Related Posts

Packaging & Logistic

VarioFill: Rotzinger sets new standards with highly flexible filling and capping platform for OTC products

30th August 2025
Major Depressive Disorder
Americas

AbbVie to Acquire Gilgamesh Pharmaceuticals’ Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline

27th August 2025
Schott-Testing
Press Statements

Carbon Reduced Pharmaceutical Glass: SCHOTT Melting Tank Construction Starts and External Certification for FIOLAX® Pro OCF

11th August 2025
GSK and Hengrui Pharma
Drug Development

GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology

29th July 2025
Aptar Pharma Bolsters Clinical Trial.
Clinical Trials

Aptar Pharma Bolsters Clinical Trial Capabilities with Strategic Materials Manufacturing Acquisition

24th July 2025
Pharma Advancement Banner
Press Statements

Welcome to the Inaugural Operationalize: Expanded Access Programs Summit West

27th June 2025
Next Post
Lilly, Incyte's Baricitinib has Significant Effect on Recovery Time, Most Impactful in COVID-19 Patients Requiring Oxygen

FDA accepts Airway Therapeutics IND application for Covid-19

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In